Drug Trial Radar · NCT01436149
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Last checked: Nov 19, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,262
Actual
Start
Oct 27, 2011
Primary completion
Dec 23, 2013
Study completion Dec 23, 2013
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 19, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions: * How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it? * Can supplemental SPD489 help patients who still have residual depression symptoms while taking an antidepressant? * How much SPD489 should be given to patients with depression who are also taking an antidepressant? * How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?
Conditions
- Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate )Drug
Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
PlaceboDrug
Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 WeeksTime frame: 8 weeks
Locations
85 sites in 6 countries. Site status is shown where the registry gives one.
Birmingham Research Group
Birmingham, Alabama
AV Institue, Inc.
Carson, California
University of California, Irvine Child Development Center
Irvine, California
South Coast Clinicals
Norwalk, California
North County Clinical Research
Oceanside, California
Pasadena Research Institute, LLC
Pasadena, California
Affiliated Research Institute
San Diego, California
Clinical Innovations, Inc.
San Diego, California
Sharp Mesa Vista Hospital
San Diego, California
Geriatric and Adult Psychiatry, LLC
Hamden, Connecticut
Middlexex Hospital Center for Behavioral Health
Middletown, Connecticut
CNS Clinical Research Group
Coral Springs, Florida
Emerald Coast Mood & Memory, PA
Fort Walton Beach, Florida
Florida Clinical Research Center, LLC.
Maitland, Florida
Suncoast Clinical Research
New Port Richey, Florida
Compass Research, LLC
Orlando, Florida
Meridien Research
St. Petersburg, Florida
Stedman Clinical Trials
Tampa, Florida
Carman Research
Smyrna, Georgia
American Medical Research, Inc.
Oak Brook, Illinois
The Davis Clinic
Indianapolis, Indiana
Northwest Indiana Center for Clinical Research
Valparaiso, Indiana
MCM Clinical Research LLC
Florence, Kentucky
Pharmasite Research, Inc.
Baltimore, Maryland
Potomac Grove Clinical Research Center
Gaithersburg, Maryland
Office of Marc Hertzman, MD
Rockville, Maryland
Adams Clinical Trials, LLC
Watertown, Massachusetts
St. Charles Psychiatric Associates - Midwest Research Group
Saint Charles, Missouri
Bioscience Research, LLC
Mount Kisco, New York
Fieve Clinical Research
New York, New York
Richmond Behavioral Associates
Staten Island, New York
Triangle Neuropsychiatry
Durham, North Carolina
Rcihard H. Weisler, MD, PA & Associates
Raleigh, North Carolina
Community Research
Cincinnati, Ohio
Lindner Center of HOPE
Mason, Ohio
SP Research, PLLC
Oklahoma City, Oklahoma
Summit Research Network (Oregon) Inc.
Portland, Oregon
Paramount Clinical Research
Bridgeville, Pennsylvania
Suburban Research Associates
Media, Pennsylvania
CRI Worldwide LLC
Philadelphia, Pennsylvania
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.